Comparison of Intravitreal Aflibercept and Ranibizumab for Treatment of Myopic Choroidal Neovascularization: One-Year Results—A Retrospective, Comparative Study
Purpose. To compare one-year treatment outcomes of intravitreal aflibercept (IVA) and intravitreal ranibizumab (IVR) for treatment of myopic choroidal neovascularization (mCNV). Methods. The medical records of a total of 30 eyes diagnosed with mCNV and underwent IVA or IVR treatment for a minimum on...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2019/8639243 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832554272504414208 |
|---|---|
| author | Burak Erden Selim Bölükbaşı Emine Baş Akın Çakır |
| author_facet | Burak Erden Selim Bölükbaşı Emine Baş Akın Çakır |
| author_sort | Burak Erden |
| collection | DOAJ |
| description | Purpose. To compare one-year treatment outcomes of intravitreal aflibercept (IVA) and intravitreal ranibizumab (IVR) for treatment of myopic choroidal neovascularization (mCNV). Methods. The medical records of a total of 30 eyes diagnosed with mCNV and underwent IVA or IVR treatment for a minimum one-year follow-up were studied retrospectively. All the subjects had an axial length >26 mm and received a 1 + PRN (pro re nata) regimen IVA or IVR. Best-corrected visual acuity (BCVA) and central macular thicknesses (CMT) on optical coherence tomography were evaluated before and after treatment. Results. There were 12 eyes in IVA group, with a mean age of 60.0 ± 10.2 years. The mean BCVA significantly improved from baseline 1.54 ± 0.76 to 0.85 ± 0.61 and the mean CMT significantly decreased from baseline 384.3 ± 119.1 μm to 305.9 ± 75.4 μm at Month 12 (p:0.024 and p:0.011, respectively). There were 18 eyes in IVR group, with a mean age of 57.4 ± 13.1 years. The mean BCVA improved from baseline 1.14 ± 0.90 to 1.04 ± 0.93 and the mean CMT significantly decreased from baseline 366.5 ± 102.3 μm to 323.6 ± 103.6 μm at Month 12 after IVR (p:0.345 and p:0.011, respectively). There was no significant difference between the groups in CMT changes in the study period (p:0.178), but IVA resulted in significantly better final visual gain (0.69 versus 0.09; p:0.006). Conclusions. Both IVA and IVR treatment modalities resulted in similar anatomical outcomes but IVA had better visual outcomes in treatment of mCNV. |
| format | Article |
| id | doaj-art-2a8373b11e8b427b9b9fd7235dcc4b38 |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-2a8373b11e8b427b9b9fd7235dcc4b382025-02-03T05:51:50ZengWileyJournal of Ophthalmology2090-004X2090-00582019-01-01201910.1155/2019/86392438639243Comparison of Intravitreal Aflibercept and Ranibizumab for Treatment of Myopic Choroidal Neovascularization: One-Year Results—A Retrospective, Comparative StudyBurak Erden0Selim Bölükbaşı1Emine Baş2Akın Çakır3University of Health Sciences, Okmeydanı Education and Research Hospital, Retina Department, Istanbul, TurkeyUniversity of Health Sciences, Okmeydanı Education and Research Hospital, Retina Department, Istanbul, TurkeyUniversity of Health Sciences, Okmeydanı Education and Research Hospital, Retina Department, Istanbul, TurkeyUniversity of Health Sciences, Okmeydanı Education and Research Hospital, Retina Department, Istanbul, TurkeyPurpose. To compare one-year treatment outcomes of intravitreal aflibercept (IVA) and intravitreal ranibizumab (IVR) for treatment of myopic choroidal neovascularization (mCNV). Methods. The medical records of a total of 30 eyes diagnosed with mCNV and underwent IVA or IVR treatment for a minimum one-year follow-up were studied retrospectively. All the subjects had an axial length >26 mm and received a 1 + PRN (pro re nata) regimen IVA or IVR. Best-corrected visual acuity (BCVA) and central macular thicknesses (CMT) on optical coherence tomography were evaluated before and after treatment. Results. There were 12 eyes in IVA group, with a mean age of 60.0 ± 10.2 years. The mean BCVA significantly improved from baseline 1.54 ± 0.76 to 0.85 ± 0.61 and the mean CMT significantly decreased from baseline 384.3 ± 119.1 μm to 305.9 ± 75.4 μm at Month 12 (p:0.024 and p:0.011, respectively). There were 18 eyes in IVR group, with a mean age of 57.4 ± 13.1 years. The mean BCVA improved from baseline 1.14 ± 0.90 to 1.04 ± 0.93 and the mean CMT significantly decreased from baseline 366.5 ± 102.3 μm to 323.6 ± 103.6 μm at Month 12 after IVR (p:0.345 and p:0.011, respectively). There was no significant difference between the groups in CMT changes in the study period (p:0.178), but IVA resulted in significantly better final visual gain (0.69 versus 0.09; p:0.006). Conclusions. Both IVA and IVR treatment modalities resulted in similar anatomical outcomes but IVA had better visual outcomes in treatment of mCNV.http://dx.doi.org/10.1155/2019/8639243 |
| spellingShingle | Burak Erden Selim Bölükbaşı Emine Baş Akın Çakır Comparison of Intravitreal Aflibercept and Ranibizumab for Treatment of Myopic Choroidal Neovascularization: One-Year Results—A Retrospective, Comparative Study Journal of Ophthalmology |
| title | Comparison of Intravitreal Aflibercept and Ranibizumab for Treatment of Myopic Choroidal Neovascularization: One-Year Results—A Retrospective, Comparative Study |
| title_full | Comparison of Intravitreal Aflibercept and Ranibizumab for Treatment of Myopic Choroidal Neovascularization: One-Year Results—A Retrospective, Comparative Study |
| title_fullStr | Comparison of Intravitreal Aflibercept and Ranibizumab for Treatment of Myopic Choroidal Neovascularization: One-Year Results—A Retrospective, Comparative Study |
| title_full_unstemmed | Comparison of Intravitreal Aflibercept and Ranibizumab for Treatment of Myopic Choroidal Neovascularization: One-Year Results—A Retrospective, Comparative Study |
| title_short | Comparison of Intravitreal Aflibercept and Ranibizumab for Treatment of Myopic Choroidal Neovascularization: One-Year Results—A Retrospective, Comparative Study |
| title_sort | comparison of intravitreal aflibercept and ranibizumab for treatment of myopic choroidal neovascularization one year results a retrospective comparative study |
| url | http://dx.doi.org/10.1155/2019/8639243 |
| work_keys_str_mv | AT burakerden comparisonofintravitrealafliberceptandranibizumabfortreatmentofmyopicchoroidalneovascularizationoneyearresultsaretrospectivecomparativestudy AT selimbolukbası comparisonofintravitrealafliberceptandranibizumabfortreatmentofmyopicchoroidalneovascularizationoneyearresultsaretrospectivecomparativestudy AT eminebas comparisonofintravitrealafliberceptandranibizumabfortreatmentofmyopicchoroidalneovascularizationoneyearresultsaretrospectivecomparativestudy AT akıncakır comparisonofintravitrealafliberceptandranibizumabfortreatmentofmyopicchoroidalneovascularizationoneyearresultsaretrospectivecomparativestudy |